Compare MMS & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MMS | ARQT |
|---|---|---|
| Founded | 1975 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.2B |
| IPO Year | 1997 | 2020 |
| Metric | MMS | ARQT |
|---|---|---|
| Price | $53.98 | $25.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $92.50 | $37.00 |
| AVG Volume (30 Days) | 548.7K | ★ 2.4M |
| Earning Date | 11-19-2026 | 10-27-2026 |
| Dividend Yield | ★ 2.48% | N/A |
| EPS Growth | 10.42 | ★ 88.79 |
| EPS | ★ 5.45 | 0.03 |
| Revenue | ★ $2,392,236,000.00 | $376,072,000.00 |
| Revenue This Year | N/A | $42.88 |
| Revenue Next Year | $2.89 | $27.84 |
| P/E Ratio | ★ $9.78 | $899.67 |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $51.04 | $19.30 |
| 52 Week High | $100.00 | $31.77 |
| Indicator | MMS | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 47.70 | 53.37 |
| Support Level | $53.19 | $24.91 |
| Resistance Level | $60.42 | $28.20 |
| Average True Range (ATR) | 1.55 | 1.44 |
| MACD | -0.17 | 0.16 |
| Stochastic Oscillator | 47.22 | 62.81 |
Maximus Inc designs, develops, and delivers programs enabling people to access vital government services. It translates health and human services public policy into operating models that achieve outcomes for governments at scale. The company covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. The company operates through the following segments: U.S. Federal Services, U.S. Services, and Outside the U.S. A majority of its revenue is derived from the U.S. Federal Services segment, which engages with various U.S. federal government agencies to deliver clinical services, maintenance services, and technology solutions.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.